Back to Authors

Weinshenker, Brian G.

https://orcid.org/0000-0001-5806-6203

Mayo Clinic

Mayo Clinic

Citations 184

Christian Confavreux (1949 – 2013)
Weinshenker, Brian G. , Clanet, Michel, Vukusic, Sandra , Weinshenker, Brian G

Multiple Sclerosis Journal | November 25, 2013 | Volume: 19 | Issue: 14 | Pages: 1811-1812

10.1177/1352458513512239 Get It

Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis
Jiao, Yujuan , Fryer, James P., Lennon, Vanda A. , McKeon, Andrew , Jenkins, Sarah M. , Quek, Amy May Lin, Weinshenker, Brian G. , Wingerchuk, Dean M. , Shuster, Elizabeth A., Lucchinetti, Claudia F. , Pittock, Sean J. , Smith, Carin Y. , Quek, Amy M L, Pittock, S J , Weinshenker, Brian G , McKeon, Andrew , Quek, Amy M.L.

JAMA Neurology | November 18, 2013 | Volume: 71 | Issue: 1 | Pages: 48

10.1001/jamaneurol.2013.5055 Get It

Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder
Flanagan, Eoin P. , Aksamit, Allen J. , Kumar, Neeraj , Morparia, Neha, Morparia, Neha P, Weinshenker, Brian G. , Keegan, B. Mark , Flanagan, E P

Neurology Clinical Practice | October 14, 2013 | Volume: 3 | Issue: 5 | Pages: 448-451

10.1212/cpj.0b013e3182a78f82 Get It

Teaching Neuro Images : “Pancake-like” gadolinium enhancement suggests compressive myelopathy due to spondylosis
Flanagan, Eoin P. , Marsh, Richard W., Weinshenker, Brian G. , Flanagan, E P , Weinshenker, Brian G

Neurology | May 20, 2013 | Volume: 80 | Issue: 21 | Pages: No page available

10.1212/wnl.0b013e318293e346 Get It

TNFRSF1A polymorphisms and MS
Weinshenker, Brian, Tienari, Pentti J. , Weinshenker, Brian G. , Weinshenker, Brian G

Neurology | April 27, 2013 | Volume: 80 | Issue: 22 | Pages: 2002-2003

10.1212/wnl.0b013e318294b4ab Get It

Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: No
Weinshenker, Brian G. , Weinshenker, Brian G

Multiple Sclerosis Journal | August 30, 2012 | Volume: 18 | Issue: 9 | Pages: 1211-1212

10.1177/1352458512458043 Get It

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
Tütüncü, Melih , Tang, Junger, Zeid, Nuhad Abou, Kale, Nilüfer , Crusan, D. J., Atkinson, Elizabeth J. , Sıva, Aksel , Pittock, Sean J. , Pirko, Istvan, Lucchinetti, Claudia F. , Noseworthy, John H., Rodriguez, Moses , Weinshenker, Brian G. , Kantarci, Orhun H. , Crusan, Daniel J. , Keegan, B. Mark , Pittock, S J , Weinshenker, Brian G , Rodriguez, Moses , Siva, Aksel

Multiple Sclerosis Journal | June 27, 2012 | Volume: 19 | Issue: 2 | Pages: 188-198

10.1177/1352458512451510 Get It

Background: It is unclear if all patients with relapsing–remitting multiple sclerosis (RRMS) ultimately develop progressive MS. Onset of progressive disease course seems to be age- rather than disease duration-dependent. Some forms of progressive MS (e.g. primary progressive MS (PPMS)) are uncommon in population-based studies. Ascertainment of patients with PPMS from clinic-based populations can facilitate a powerful comparison of age at progression onset between secondary progressive MS (SPMS) and PPMS but may introduce unclear biases. Objective: Our aim is to confirm that onset of progressive disease course is more relevant to the patient’s age than the presence or duration of a pre-progression relapsing disease course in MS. Methods: We studied a population-based MS cohort ( n =210, RRMS n =109, progressive MS n =101) and a clinic-based progressive MS cohort ( n =754). Progressive course was classified as primary (PPMS; n =322), single attack (SAPMS; n =112) and secondary progressive (SPMS; n =421). We studied demographics (chi 2 or t -test), age-of-progression-onset ( t -test) and time to Expanded Disability Status Scale of 6 (EDSS6) (Kaplan–Meier analyses). Results: Sex ratio ( p =0.58), age at progression onset ( p =0.37) and time to EDSS6 ( p =0.16) did not differ between the cohorts. Progression had developed before age 75 in 99% of patients with known progressive disease course; 38% with RRMS did not develop progression by age 75. Age at progression onset did not differ between SPMS (44.9±9.6), SAPMS (45.5±9.6) and PPMS (45.7±10.8). In either cohort, only 2% of patients had reached EDSS6 before onset of progression. Conclusions: Patients with RRMS do not inevitably develop a progressive disease course. Onset of progression is more dependent on age than the presence or duration of a pre-progression symptomatic disease course. Moderate disability is sustained predominantly after the onset of a progressive disease course in MS.
Interferon beta-1b in secondary progressive MS
Kappos, Ludwig , Weinshenker, Brian G. , Pozzilli, Carlo , Thompson, Alan J. , Beckmann, K., Polman, Chris H. , McFarland, Henry F. , Dahlke, Frank , Weinshenker, Brian G , Pozzilli, Carlo

Neurology | May 13, 2012 | Volume: 63 | Issue: 10 | Pages: 1779-1787

10.1212/01.wnl.0000145561.08973.4f Get It

Association of APOE polymorphisms with disease severity in MS is limited to women
Kantarci, Orhun H. , Hebrink, David D., Achenbach, Sara J., Pittock, S J , Altıntaş, Ayşe , Schaefer-Klein, Janet, Atkinson, Elizabeth J. , McMurray, Cynthia T. , Weinshenker, Brian G. , Pittock, Sean J. , Andrade, Mariza de , Rodriguez, Moses , Weinshenker, Brian G

Neurology | May 13, 2012 | Volume: 62 | Issue: 5 | Pages: 811-814

10.1212/01.wnl.0000113721.83287.83 Get It